Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for age-related degenerative diseases, with an emphasis on disorders of the central nervous system and the retina. The company’s lead candidate is CT1812, an orally administered molecule modulator designed to cross the blood-brain barrier and selectively bind to the S2R complex. CT1812 is being evaluated in Phase 2 studies for Alzheimer’s disease, geographic atrophy associated with dry age-related macular degeneration, and synucleinopathies, including dementia with Lewy bodies. Cognition Therapeutics was incorporated in 2007 and is headquartered in Purchase, New York. Its common stock trades on the NASDAQ under the symbol CGTX.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CGTX
|
$0.85
|
-18.6% Downside
|
Overvalued
|
$3.33
|
220.5% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
3.0x
|
99.373 M
|
65.474 M
|
0.6%
|
91.9%
|
0.8
|
105.5%
|
